... regarding the blockbuster potential of Rayaldy, its treatment for thyroid disorder, chronic kidney disease, and vitamin D deficiency. Opko is unprofitable, but it has already generated $75.8 million in revenue over the first three quarters of fiscal ...
http://ift.tt/LYTqHB
http://ift.tt/LYTqHB
No comments:
Post a Comment